Skip to main content
Lyrea avatar

Not yet reviewed — this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

Flurazepam

This article is a stubmissing:
Subjective Effects
Pharmacology
Tolerance
History & Culture
Flurazepam molecule structureFlurazepam molecule structure
7-Chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
Dalmane, Dalmadorm

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~5 mg
Light5-10 mg
Moderate15-30 mg
Strong30-60 mg
Heavy60+ mg

Duration

Onset45-90 minutes
After Effects2-48 hours
Total12-16 hours

Subjective Effects

Subjective Effects not written up yet

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Froe(FR)
white → orange2
Zimm(ZI)
white → pink1 → purple2
Powered by PROtestkit.eu

Pharmacology

Pharmacology not written up yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AlcoholGHB/GBLOpioidsTramadol

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

DXMKetamineMXE
Powered by TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Addiction & Dependence

Psychological

High

Flurazepam has significant abuse potential with risk of psychological dependence. Recreational misuse occurs where the drug is taken to achieve a high, and continued use against medical advice is common. The FDA required a boxed warning describing risks of abuse, misuse, and addiction for all benzodiazepines.

Physical

High

Long-term use is associated with drug tolerance and physical dependence. After discontinuation, a rebound effect or benzodiazepine withdrawal syndrome may occur approximately four days after stopping medication. Flurazepam shares cross tolerance with barbiturates, indicating significant physical dependence potential.

Toxicity

Lethal Dosage

Flurazepam combined with alcohol or other CNS depressants may produce fatal results. Overdose symptoms include coma, confusion, low blood pressure, and severe sleepiness.

Central Nervous System

Chronic use causes cognitive impairment including anterograde amnesia, daytime sedation, and motor incoordination; these effects may persist as residual hangover effects after nighttime administration and impair next-day functioning.

Musculoskeletal

Use is associated with impairments in body balance and standing steadiness, leading to increased risk of falls and hip fractures, particularly in individuals who wake at night or the next morning.

Immune

In a meta-analysis, people using hypnotic drugs had 44% more mild infections, including examples such as pharyngitis and sinusitis, than those receiving placebo.

Psychosis Risk

Low

Paradoxical agitation or disinhibition may occur, particularly in elderly patients, though this is considered a moderately higher risk compared to non-benzodiazepine sedatives rather than a common occurrence.

History & Culture

History & Culture not written up yet

Legality

International

Controlled internationally under the UN Convention on Psychotropic Substances 1971.

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed — this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest

Times are UTCNewest first

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Flurazepam article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.